Parkinson, Servier exercises the exclusive licensing option on collaborative program with Oncodesign Precision Medicine

server and Oncodesign Precision Medicine (OPM) specializing in precision medicine server It has exercised its choice to grant exclusive license to its drug candidate, an inhibitor of the LRRK2 target kinase, the result of their collaboration in the treatment of Parkinson’s disease.

in March 2019And the server OPM and OPM have initiated a research and development collaboration on LRRK2 kinase inhibitors, as potential therapeutic agents for Parkinson’s disease. This collaboration is based on the complementary expertise of server The OPM in neurodegenerative diseases and kinase inhibitors. in June 2021The two companies announced the selection of a preclinical candidate drug. learn more

Read:Epidural lidocaine injections show promise for treating psoriasis

server It expects to start a “phase one study in healthy volunteers” before the end of 2022.

Ross JejuPh.D., Global Head of Neuroscience and Therapeutic Area of ​​Immune Inflammation: “The progress of the research and development program for this candidate drug for Parkinson’s disease is the result of the experience shared between server and her partner Oncodesign. This collaboration reflects the group’s commitment to focus its research on diseases with high medical needs, and to work closely with partners who share their knowledge and techniques to create innovative synergies and accelerate the discovery of therapeutic solutions for the benefit of patients.

Read:Covid warning over symptom that impacts your sleep as cases skyrocket across UK


Tel: 01 55 72 60 00

(c) 2022 e-newsletter, source ENP Newswire

Previous post
Christmas shopping chaos looms as Royal Mail staff plan 19 days of walkouts
Next post
Manchester United have unknown quantity that can give advantage vs Pep Guardiola and Man City